RNXT RenovoRx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNXT

Price (delayed)

$1.63

Market cap

$73.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$64.34M

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 19

RenovoRx, Inc. is a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet ...

Highlights
The company's revenue has surged by 198% YoY and by 33% QoQ
RNXT's gross profit is up by 42% since the previous quarter
RenovoRx's debt has surged by 61% YoY
The quick ratio has contracted by 35% YoY and by 20% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://renovorx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RNXT

RNXT stock price

How has the RenovoRx stock price performed over time
Intraday
-4.12%
1 week
5.16%
1 month
23.48%
1 year
32.52%
YTD
94.02%
QTD
66.33%

Financial performance

How have RenovoRx's revenue and profit performed over time
Revenue
$1.98M
Gross profit
$1.67M
Operating income
-$13.54M
Net income
-$12.29M
Gross margin
84.4%
Net margin
-621.7%
The company's revenue has surged by 198% YoY and by 33% QoQ
RenovoRx's net margin has surged by 61% YoY and by 25% QoQ
The company's operating margin has surged by 60% YoY and by 21% QoQ
RNXT's gross profit is up by 42% since the previous quarter

Price vs fundamentals

How does RNXT's price correlate with its fundamentals

Growth

What is RenovoRx's growth rate over time

Valuation

What is RenovoRx stock price valuation
P/E
N/A
P/B
8.19
P/S
39.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.56
The EPS has grown by 18% YoY and by 6% from the previous quarter
The P/B is 93% below the 5-year quarterly average of 129.6 but 67% above the last 4 quarters average of 5.1
The company's equity fell by 20% QoQ and by 16% YoY
The company's revenue has surged by 198% YoY and by 33% QoQ
The P/S is 29% higher than the last 4 quarters average of 31.5

Efficiency

How efficient is RenovoRx business performance
The ROS has soared by 61% YoY and by 25% from the previous quarter
RNXT's ROA is down by 23% YoY and by 5% from the previous quarter
RNXT's ROE is down by 21% YoY and by 5% QoQ

Dividends

What is RNXT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNXT.

Financial health

How did RenovoRx financials performed over time
The quick ratio has contracted by 35% YoY and by 20% from the previous quarter
The current ratio has declined by 33% year-on-year and by 20% since the previous quarter
RenovoRx's debt is 97% lower than its equity
The debt to equity has soared by 200% from the previous quarter and by 50% YoY
RenovoRx's debt has surged by 61% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.